- Home
- DDS vs BPMC Comparison
DDS vs BPMC Comparison
Compare DDS & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DDS
- BPMC
- Stock Information
- Founded
- DDS 1938
- BPMC 2008
- Country
- DDS United States
- BPMC United States
- Employees
- DDS N/A
- BPMC N/A
- Industry
- DDS Department/Specialty Retail Stores
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- DDS Consumer Discretionary
- BPMC Health Care
- Exchange
- DDS Nasdaq
- BPMC Nasdaq
- Market Cap
- DDS 7.0B
- BPMC 5.8B
- IPO Year
- DDS N/A
- BPMC 2015
- Fundamental
- Price
- DDS $363.47
- BPMC $90.01
- Analyst Decision
- DDS Sell
- BPMC Buy
- Analyst Count
- DDS 2
- BPMC 22
- Target Price
- DDS $326.00
- BPMC $124.29
- AVG Volume (30 Days)
- DDS 179.4K
- BPMC 950.3K
- Earning Date
- DDS 05-15-2025
- BPMC 05-01-2025
- Dividend Yield
- DDS 0.28%
- BPMC N/A
- EPS Growth
- DDS N/A
- BPMC N/A
- EPS
- DDS 36.82
- BPMC N/A
- Revenue
- DDS $6,590,231,000.00
- BPMC $508,824,000.00
- Revenue This Year
- DDS N/A
- BPMC $45.43
- Revenue Next Year
- DDS N/A
- BPMC $32.80
- P/E Ratio
- DDS $9.88
- BPMC N/A
- Revenue Growth
- DDS N/A
- BPMC 104.04
- 52 Week Low
- DDS $328.00
- BPMC $80.68
- 52 Week High
- DDS $510.00
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- DDS 39.47
- BPMC 47.63
- Support Level
- DDS $346.74
- BPMC $84.55
- Resistance Level
- DDS $366.66
- BPMC $93.04
- Average True Range (ATR)
- DDS 13.04
- BPMC 3.55
- MACD
- DDS 3.59
- BPMC 0.19
- Stochastic Oscillator
- DDS 55.90
- BPMC 47.60
About DDS Dillard's Inc.
Dillard's Inc is an American fashion apparel, cosmetics, and home furnishings retailer. Its stores offer a large variety of merchandise and feature products from both national and exclusive brand sources. The company also operates a general contracting construction company, CDI Contractors. CDI Contractors' business includes constructing and remodelling stores for Dillards. The merchandise selections include exclusive brand merchandise such as Antonio Melani, Gianni Bini, Daniel Cremieux, Roundtree & Yorke, and private-label merchandise, among others. The company operates in two business segments; Retail Operations and Construction. The Retail Operations segment generates maximum revenue for the company.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.